9.67
+0.02(+0.21%)
Currency In USD
| Previous Close | 9.65 |
| Open | 9.66 |
| Day High | 9.69 |
| Day Low | 9.5 |
| 52-Week High | 18.37 |
| 52-Week Low | 7.87 |
| Volume | 140,855 |
| Average Volume | 115,111 |
| Market Cap | 139.45M |
| PE | -9.77 |
| EPS | -0.99 |
| Moving Average 50 Days | 9.35 |
| Moving Average 200 Days | 11.96 |
| Change | 0.02 |
If you invested $1000 in Anika Therapeutics, Inc. (ANIK) 10 years ago, it would be worth $233.97 as of November 19, 2025 at a share price of $9.67. Whereas If you bought $1000 worth of Anika Therapeutics, Inc. (ANIK) shares 5 years ago, it would be worth $264.64 as of November 19, 2025 at a share price of $9.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
GlobeNewswire Inc.
Nov 05, 2025 12:00 PM GMT
BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module of its Premarket Approval application (P
Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025
GlobeNewswire Inc.
Oct 23, 2025 8:01 PM GMT
BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
GlobeNewswire Inc.
Jul 30, 2025 11:00 AM GMT
Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed statistically significant improvem